Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe

Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical
Company Limited (Osaka, Japan, "Takeda") announced today it will
establish four new commercial subsidiaries covering Mexico, Turkey,
Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries
- Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals
Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and
Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's
strategic global expansion efforts.

"Takeda has a significant opportunity to expand our presence in
Mexico, Europe and other priority markets," said Alan MacKenzie,
Executive Vice President (EVP) International Operations, Takeda
Pharmaceuticals International, Inc. "Executing our territory
expansion strategy is an important step toward further globalizing
our operations and enhancing our ability to bring important medicines
to patients who need them."

The Mexican pharmaceutical market is the 12th largest in the
world and accounts for approximately 25 percent of the pharmaceutical
sales throughout Latin America. The population in Mexico is
increasing, and access to healthcare continues to grow, with the
market increasing faster than in the United States and Europe, making
it a key region for Takeda's expansion.

Nordics and Benelux are strategically important regions in Europe
- Norway, Sweden, Denmark, Belgium and Luxembourg have a combined
pharmaceutical market size which accounts for five percent of the
European pharmaceutical market. Following the buy-back of Actos(R)
(pioglitazone) in October 2008, Takeda will be distributing Actos in
the five countries. The creation of these commercial subsidiaries
will further increase Takeda's reach in the regions.

The Turkish pharmaceutical market is one of the largest global
pharmaceutical markets, ranked sixth in Europe and 13th worldwide
with the fastest forecasted growth rate in Europe over the next five
years. Takeda also recently re-acquired the rights to Actos in this
market, providing the business with a strong product with which to
enter the market.

Overall, the new subsidiaries will accelerate Takeda's expansion
efforts for core products including Actos and reinforces Takeda's
global operating infrastructure. The company will work toward the
earliest possible approval and launch of new products in these
regions. Takeda's presence in these seven new countries builds upon
other expansions announced in 2009 including commercial operations in
Spain, Portugal, Ireland, and Canada.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global
company with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to striving toward better health for
individuals and progress in medicine by developing superior
pharmaceutical products. Takeda is enhancing its R&D pipeline by
concentrating its management resources in the following selected core
therapeutic areas: lifestyle-related diseases, oncology and
urological diseases (including gynecology), central nervous system
diseases (including bone and joint disorders), and
gastroenterological diseases. For more information, please visit
http://www.takeda.com/.

About Takeda Pharmaceuticals Mexico, S.A. de C.V.
Name: Takeda Pharmaceuticals Mexico, S.A. de C.V.
Location: Mexico city, Mexico
Established: October 2009
About Takeda Pharmaceuticals Nordics AB
Name: Takeda Pharmaceuticals Nordics AB
Location: Sweden
Established: October 2009
About Takeda Pharmaceuticals Benelux SPRL
Name: Takeda Pharmaceuticals Benelux SPRL
Location: Belgium
Established: October 2009
About Takeda Pharmaceuticals Trade, LLP
Name: Takeda Pharmaceuticals Trade, LLP
Location: Istanbul, Turkey
Established: October 2009
Contacts:
Seizo Masuda
Takeda Pharmaceutical Company Limited
+81-3-3278-2037 (office)
Angela Bechan
Takeda Pharmaceuticals North America, Inc.
+1-224-554-5467

ots Originaltext: Takeda Pharmaceutical Company Limited
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Seizo Masuda, Takeda Pharmaceutical Company Limited,
+81-3-3278-2037 (office); Angela Bechan, Takeda Pharmaceuticals North
America, Inc., +1-224-554-5467